First-line treatment of advanced renal cell carcinoma Innovative immuno combination therapy submitted regulatory applications.

Globally, about 71,000 patients will need systemic treatment for advanced kidney cancer by 2020.
if found at an early stage, the five-year survival rate of RCC was high, while in patients with late or late metastasis RCC, the five-year survival rate was only 12%.
transparent cell RCC is the most common type of kidney cancer in adults.
about 70% of RCC cases are transparent cell RCC, according to histology.
levels of a protein called von Hippel-Lindau in most transparent cell RCC tumors are lower than normal, leading to elevated levels of MET, AXL, and VEGF.
these proteins promote angiogenesic, growth, immersion and tumor metastasis.
met and AXL may drive tumor resistance to VEGF inhibitors.
Cabozantinib is a tyrosine kinase inhibitor that inhibits VEGFR-1/2/3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.
has been approved by the FDA as a single drug to treat patients with advanced RCC and hepatocellular carcinoma.
sNDA is based on a critical Phase 3 clinical trial called CheckMate-9ER.
it assessed the efficacy and safety of Cabometyx in the treatment of patients with the previously untreated late stage or metastasis RCC in a joint use with the PD-1 inhibitor Opdivo.
Exelixis and Shishi Meishiguibo announced in April 2020 that the trial had reached its primary endpoint, significantly improving patient progression-free survival (PFS) at the time of final analysis, and achieving objective mitigation rates (ORRs) and secondary endpoints of total survival (OS) at pre-defined interim analyses.
results of the trial will be presented at this year's European EsMO congress.
: Exelixis Announces Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for CABOMETYX® (cabozantinib) in With With With Opdivo ® (nivolumab) for Advanced Renal Cell Caromacin. Retrieved August 24, 2020, from.